secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVAI BIO, INC. (AVAI)
CIK:        0001740797
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001740797-25-000049
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avant Technologies forms joint venture Insulinova with Austrianova for diabetes cell therapy
--------------------------------------------------------------------------------

- AVAI and Austrianova each hold 50% of Insulinova, a JV for encapsulated insulin cell diabetes treatments.
- AVAI contributes up to $1.5M in capital over 18 months for operations, plus an optional $8.5M loan for clinical testing.
- Austrianova provides exclusive license to its cell encapsulation technology; Kenn Kerr CEO, Walter Günzburg Chairman.
- This agreement supersedes the prior JV from Sept 19, 2025, which included Art-Islets as a party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740797/000174079725000049/0001740797-25-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740797/000174079725000049/avai_8k.htm
  HTML page:      https://secwatch.observer/filing/0001740797-25-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer